![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
NIAID ChemDB | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C9H12N6O3 |
Molar mass | 252.234 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Amdoxovir is a pharmaceutical drug that has undergone research for the treatment of HIV/AIDS. It acts as a nucleoside reverse transcriptase inhibitor (NRTI). The drug was discovered by Raymond F. Schinazi (Emory University) and C.K. Chu (University of Georgia) and developed by RFS Pharma.[1]
Amdoxovir was in advanced Phase II clinical trials around 2010.[2] In 2013, a Phase II trial was terminated[3] and another was withdrawn before it started.[4] No further studies appear to have been done.
References
[edit]- ^ "Amdoxovir". AIDSmeds.com. January 13, 2009. Archived from the original on 2008-03-21. Retrieved March 21, 2008.
- ^ Murphy RL, Kivel NM, Zala C, Ochoa C, Tharnish P, Mathew J, Pascual ML, Schinazi RF (2010). "Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals". Antivir Ther. 15 (2): 185–192. doi:10.3851/IMP1514. PMC 7733239. PMID 20386073.
- ^ Clinical trial number NCT01737359 for "A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects" at ClinicalTrials.gov
- ^ Clinical trial number NCT01738555 for "A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects" at ClinicalTrials.gov